Market Access NHS to offer Wegovy to a million more people in England PharmaphorumThe NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.Market AccessMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes. Market AccessMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MDNext: ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026
